protein tyrosine phosphatase non-receptor type 23Genealiases: HD-PTP · HDPTP · NEDBASS · PTP-TD14
Q-omics provides the consensus-scored PTPN23 profile across patient tissues and cancer cell-line models. PTPN23 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PTPN23 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PTPN23 RNA expression shows 20,227 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where PTPN23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN23 survival associations across molecular data types. PTPN23 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN23 RNA expression–survival associations across cancer types. High PTPN23 expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in UVM, BRCA and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PTPN23 RNA expression.
This table summarizes PTPN23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN23 shows lower tumor expression in KIRC and higher tumor expression in COAD, LIHC, STAD, BLCA and BRCA. The COAD box plot shows higher PTPN23 RNA expression in tumor versus normal tissue (log2 FC = +0.570, t-test p < 0.001).
This table shows molecular features associated with PTPN23 in patient tissues and cancer cell lines. In patient samples, PTPN23 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
